Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients

Adverse events of immune checkpoint therapy alone versus when combined with vascular endothelial growth factor inhibitors: a pooled meta-analysis of 1735 patients

BackgroundCombining immune checkpoint therapy (ICT) and vascular endothelial growth factor inhibitors (VEGFi) may result in increased treatment-related and immune-related adverse events (TRAEs and irAEs) compared to ICT alone. This metanalysis was conducted to identify prospective phase II or III cl...

Full description

Bibliographic Details
Main Authors: Iuliia Kovalenko, Wern Lynn Ng, Yimin Geng, Yinghong Wang, Pavlos Msaouel, Shailender Bhatia, Petros Grivas, Raed Benkhadra, Omar Alhalabi
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-01-01
Series:Frontiers in Oncology
Subjects:
cancer
immunotherapy
toxicity
adverse events
immune checkpoint inhibitor
vascular endothelial - growth factor
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2023.1238517/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2023.1238517/full

Similar Items